Navigation Links
Omeros to Present at the 12th Annual Needham Healthcare Conference
Date:4/24/2013

SEATTLE, April 24, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12th Annual Needham Healthcare Conference next week.  Gregory A. Demopulos , M.D., chairman and chief executive officer, is scheduled to present at 8:40 a.m. Eastern Time on Wednesday, May 1, 2013.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
2. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
5. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
6. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
10. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
11. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... , ... (PRWEB) September 21, 2017 , ... ... international scientific and technical congress to review the latest knowledge on these products, ... prestigious international speakers will discuss the impact of Biostimulants on Plant Nutrition, Abiotic ...
(Date:9/21/2017)... , ... September 21, 2017 , ... Lajollacooks4u welcomed the ... The organization, a worldwide society of professional women with high achievement in the ... its annual dinner. , Twelve members began with an olive oil tasting ...
(Date:9/20/2017)... Bell, PA and College Station, TX (PRWEB) , ... ... ... IPS-Integrated Project Services, LLC (IPS), a leading global provider of ... Manufacturing, Inc. the leading provider of prefabricated cleanrooms, today announced the unveiling ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading independent provider ... opening of an office in Taipei, Taiwan. This new location allows RoviSys to ... new relationships in the region. Located in the Neihu area of Taipei, the ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):